Log in

NASDAQ:OTICOtonomy Stock Price, Forecast & News

$2.56
-0.05 (-1.92 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.53
Now: $2.56
$2.89
50-Day Range
$1.95
MA: $2.28
$2.61
52-Week Range
$1.53
Now: $2.56
$4.18
Volume95,141 shs
Average Volume67,586 shs
Market Capitalization$79.03 million
P/E RatioN/A
Dividend YieldN/A
Beta2.31
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase I/II clinical trial to treat tinnitus; and OTO-413, a proprietary formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. In addition, the company develops OTO-510, a sustained-exposure formulation of small molecule otoprotectant for the prevention of cisplatin-induced hearing loss; and OTO-6XX induces hair cell regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.
Read More
Otonomy logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OTIC
CUSIPN/A
Phone619-323-2200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$600,000.00
Book Value$0.97 per share

Profitability

Net Income$-44,670,000.00
Net Margins-7,826.41%

Miscellaneous

Employees49
Market Cap$79.03 million
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive OTIC News and Ratings via Email

Sign-up to receive the latest news and ratings for OTIC and its competitors with MarketBeat's FREE daily newsletter.

Otonomy (NASDAQ:OTIC) Frequently Asked Questions

How has Otonomy's stock been impacted by COVID-19 (Coronavirus)?

Otonomy's stock was trading at $2.62 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OTIC stock has decreased by 2.3% and is now trading at $2.56. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Otonomy?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Otonomy.

When is Otonomy's next earnings date?

Otonomy is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Otonomy.

How were Otonomy's earnings last quarter?

Otonomy Inc (NASDAQ:OTIC) issued its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.02. The biopharmaceutical company had revenue of $0.16 million for the quarter. Otonomy had a negative return on equity of 98.90% and a negative net margin of 7,826.41%. View Otonomy's earnings history.

What price target have analysts set for OTIC?

3 brokerages have issued 12 month target prices for Otonomy's shares. Their forecasts range from $8.00 to $8.00. On average, they anticipate Otonomy's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 212.5% from the stock's current price. View analysts' price targets for Otonomy.

Has Otonomy been receiving favorable news coverage?

Media stories about OTIC stock have been trending negative recently, InfoTrie reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Otonomy earned a news impact score of -2.8 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutOtonomy.

Are investors shorting Otonomy?

Otonomy saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 137,800 shares, a decrease of 14.1% from the April 30th total of 160,400 shares. Based on an average daily trading volume, of 134,900 shares, the short-interest ratio is currently 1.0 days. Currently, 0.6% of the shares of the stock are short sold. View Otonomy's Current Options Chain.

Who are some of Otonomy's key competitors?

What other stocks do shareholders of Otonomy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include Canaccord Genuity (), BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird () and Wellington Shields ().

Who are Otonomy's key executives?

Otonomy's management team includes the following people:
  • Dr. Jay B. Lichter, Co-Founder & Chairman (Age 57)
  • Dr. David Allen Weber, Pres, CEO & Director (Age 59)
  • Mr. Paul E. Cayer, Chief Financial & Bus. Officer (Age 57)
  • Mr. Robert Michael Savel II, Chief Technical Officer (Age 51)
  • Dr. Allen F. Ryan Ph.D., Co-Founder and Member of the Advisory Panel

What is Otonomy's stock symbol?

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

Who are Otonomy's major shareholders?

Otonomy's stock is owned by a number of institutional and retail investors. Top institutional investors include First Manhattan Co. (3.26%), BlackRock Inc. (2.58%), Granahan Investment Management Inc. MA (0.54%), Acadian Asset Management LLC (0.52%), Mercer Global Advisors Inc. ADV (0.29%) and Orbimed Advisors LLC (0.23%). View institutional ownership trends for Otonomy.

Which institutional investors are selling Otonomy stock?

OTIC stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co., Orbimed Advisors LLC, Mercer Global Advisors Inc. ADV, and BlackRock Inc.. View insider buying and selling activity for Otonomy.

Which institutional investors are buying Otonomy stock?

OTIC stock was bought by a variety of institutional investors in the last quarter, including Granahan Investment Management Inc. MA, Acadian Asset Management LLC, Connor Clark & Lunn Investment Management Ltd., Ensign Peak Advisors Inc, and JPMorgan Chase & Co.. View insider buying and selling activity for Otonomy.

How do I buy shares of Otonomy?

Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Otonomy's stock price today?

One share of OTIC stock can currently be purchased for approximately $2.56.

How big of a company is Otonomy?

Otonomy has a market capitalization of $79.03 million and generates $600,000.00 in revenue each year. The biopharmaceutical company earns $-44,670,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. Otonomy employs 49 workers across the globe.

What is Otonomy's official website?

The official website for Otonomy is www.otonomy.com.

How can I contact Otonomy?

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.